Gyre Therapeutics stock falls 5.00 percent to USD 6.08 on October 16, 2026

Published on 10/17/2026 at 20:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 29.11 million. Gyre Therapeutics stock costs USD 6.08 on October 16, 2026, down 5.00 percent versus USD 6.40.

Nasdaq session falls 5.00 percent

Gyre Therapeutics stock fell 5.00 percent on October 16, 2026.
Second-quarter revenue reached USD 29.11 million in 2026.
Gyre Therapeutics stock last stood at USD 6.08 on October 16, 2026 at 4:00 p.m. ET, down 5.00 percent versus the prior Nasdaq close of USD 6.40.
MarketBeat estimates the next report for November 6, 2026.

GYRE, US4037831033, Illustration mit AI erstellt.

Gyre Therapeutics stock fell 5.00 percent to USD 6.08 on October 16, 2026, its latest Nasdaq session. The move leaves the biotechnology company 11.76 percent above its 52-week low of USD 5.44 and 33.48 percent below its high of USD 9.14. The latest price was USD 6.08 at 4:00 p.m. ET.

Revenue reached USD 29.11 million

Gyre reported second-quarter 2026 revenue of USD 29.11 million, above the USD 26.49 million analyst estimate, according to EODHD. The same results update listed GAAP basic earnings per share at minus USD 0.12 and full-year 2026 revenue guidance of USD 100.5 million to USD 111.0 million.

That combination gives the stock a mixed operating profile. Revenue exceeded the comparison estimate by USD 2.62 million, while the quarterly loss was wider than the consensus loss of USD 0.06 per share, according to MarketBeat.

Range and valuation remain important

Gyre's latest price is USD 0.64 above its 52-week low and USD 3.06 below its 52-week high. Trading volume reached 142,874 shares on October 16, 2026, compared with an average volume of 110,571 shares. The company had a market capitalization of USD 644.7 million.

Valuation and reporting date

The trailing P/E ratio was minus 30.13 on October 16, 2026, while the company paid no dividend yield. MarketBeat estimates the next quarterly report for November 6, 2026, before the market opens, with a conference call scheduled for 9:30 a.m. ET. Its estimate calls for revenue of USD 28.40 million and a loss of USD 0.15 per share.

Comparison with peers

Gyre Therapeutics (Nasdaq, USD): minus 5.00 percent, P/E minus 30.13, market capitalization USD 644.7 million

Evolus (Nasdaq, USD): minus 6.21 percent, P/E minus 13.71, market capitalization USD 469.0 million

Viking Therapeutics (Nasdaq, USD): minus 8.04 percent, P/E minus 5.40, market capitalization USD 3.2 billion

Latest market position

Gyre Therapeutics last stood at USD 6.08 on October 16, 2026 at 4:00 p.m. ET, down 5.00 percent versus the prior Nasdaq close of USD 6.40. The stock remains above its yearly low while its latest quarterly loss and November reporting date provide the next dated reference points.